3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Myeloproliferative Disorders
2
Leukemia, Myelomonocytic, Chronic
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Esophageal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Rituximab
56
Cyclophosphamide
39
fludarabine
23
fludarabine phosphate
18
Peripheral Blood Stem Cell Transplantation
17
Lenalidomide
14
Melphalan
13
Etoposide
12
venetoclax
11
Whole-Body Irradiation
11
Mycophenolic Acid
11
obinutuzumab
10
Vincristine
10
Prednisone
10
Bendamustine Hydrochloride
10
Doxorubicin
9
Cytarabine
9
Cyclosporine
9
Bortezomib
9
Filgrastim
8
pembrolizumab
7
Nivolumab
7
Gemcitabine
7
Busulfan
7
acalabrutinib
6
Tacrolimus
6
Interleukin-2
6
Dexamethasone
6
Carmustine
6
Alemtuzumab
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Lymphoma, Non-Hodgkin
×
eprenetapopt
×
Clear all
NCT04419389
2025-03-17
R/R
Aprea Therapeutics
Phase 1/2
Terminated
1 enrolled
4 charts